Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for blood sugar reduction in type 2 diabetes with ischemic heart disease
IRCT20161026030511N3Phase 3Completed
- Sponsor
- Samin Darou Iranian
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranolazine in type 2 diabetes mellitus (T2DM), stable angina and coronary arteriosclerosis (2 arms), sponsored by Samin Darou Iranian. Primary endpoint: Reduction of HbA1c. Started Jun 2016; status: completed.
02
Drugs
ranolazine
03
Conditions
type 2 diabetes mellitus (T2DM)stable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20161026030511N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161026030511N3.